Replicon Technologies, Inc.

Birmingham, AL 35223

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $766K
First Award Date 09/01/98
Most Recent Award Date 01/01/03

Key Personnel

Last Name Name Awards Contact
Porter Donna C Porter 4
Ansardi David C Ansardi 2

6 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/03 - 07/31/03

DESCRIPTION (PROVIDED BY APPLICANT): Reports from the US indicate that more than 8 million people in this country are currently battling or have had cancer. Replicon Technologies, Incorporated (RTI) has developed a unique gene therapy strategy based on RNA vectors (replicons) with the potential to overcom...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/18/02 - 12/31/02

DESCRIPTION (PROVIDED BY APPLICANT): Reports from the US indicate that more than 8 million people in this country are currently battling or have had cancer. Replicon Technologies, Incorporated (RTI) has developed a unique gene therapy strategy based on RNA vectors (replicons) with the potential to overcom...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/01 - 12/31/01

DESCRIPTION (PROVIDED BY APPLICANT): Reports from the US indicate that more than 8 million people in this country are currently battling or have had cancer. Replicon Technologies, Incorporated (RTI) has developed a unique gene therapy strategy based on RNA vectors (replicons) with the potential to overcom...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/03/99 - 08/31/00

The prognosis for patients diagnosed with malignant glioma has remained very poor despite recent advances in traditional surgical, radiation, and chemical therapies. Novel suicide gene therapies for gliomas have shown promise in pre-clinical studies; however, the development of effective delivery systems is critical to ensure their success. W...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/21/98 - 12/20/99

Despite technical advances in neurosurgery, radiotherapy and the development of novel drugs, the outcome for malignant glioma patients has not improved during the last few decades. The development of effective delivery systems for therapeutics directly to brain tumors is critical for patient...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/98 - 11/30/99

DESCRIPTION: The development of effective delivery systems for therapeutics to the CNS is critical for AIDS patients with AIDS Dementia Complex-associated dysfunction. Practical treatments for ADC may be more effective if enacted locally within the CNS to avoid the problems associated with systemi...